Follicular Lymphoma Clinical Trials

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED
N
Recruiting
  • Follicular Lymphoma
  • +3 more
  • CD22-CAR
  • Bethesda, Maryland
    National Institutes of Health Clinical Center, 9000 Rockville Pi
2022-04-07
Apr 7, 2022
N
Suspended
  • Follicular Lymphoma
  • +4 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
2022-04-07
Apr 7, 2022
N
Recruiting
  • Follicular Lymphoma
  • +2 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
2022-04-07
Apr 7, 2022
F
Recruiting
  • Follicular Lymphoma
  • Immunochemotherapy regimen: Rituximab-bendamustine (Arm A)
  • +9 more
  • Barletta, Barletta Andria Trani, Italy
  • +68 more
2022-03-30
Mar 30, 2022
G
Recruiting
  • Diffuse Large B-Cell Lymphoma
  • Follicular Lymphoma
  • rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone
  • +7 more
  • Birmingham, Alabama
  • +60 more
2022-04-01
Apr 1, 2022
A
Not yet recruiting
  • Follicular Lymphoma
  • +2 more
  • ClonoSEQ
  • Palo Alto, California
    Stanford Cancer Center
2022-04-04
Apr 4, 2022
J
Recruiting
  • Non-Hodgkin Lymphoma
  • +4 more
  • JCAR017 (lisocabtagene maraleucel) single-dose schedule
  • JCAR017 (lisocabtagene maraleucel) 2-dose schedule
  • Birmingham, Alabama
  • +13 more
2022-03-28
Mar 28, 2022
B
Not yet recruiting
  • Follicular Lymphoma
  • +2 more
  • New Haven, Connecticut
  • +2 more
2022-03-14
Mar 14, 2022
Q
Recruiting
  • Follicular Lymphoma
  • +7 more
  • Louisville, Kentucky
  • +4 more
2022-03-11
Mar 11, 2022
I
Recruiting
  • Non-Hodgkin Lymphoma
  • +4 more
  • Duarte, California
  • +12 more
2022-03-24
Mar 24, 2022
J
Enrolling by invitation
  • Chronic Lymphocytic Leukemia
  • +6 more
  • Duarte, California
  • +165 more
2022-03-24
Mar 24, 2022
S
Recruiting
  • Follicular Lymphoma
  • Relapsed and Refractory Follicular Lymphoma
  • Guangzhou, Guangdong, China
  • +2 more
2022-03-23
Mar 23, 2022
C
Recruiting
  • Chronic Lymphocytic Leukemia
  • +6 more
  • Duarte, California
  • +2 more
2022-03-09
Mar 9, 2022
Z
Recruiting
  • Relapsed Chronic Lymphocytic Leukemia
  • +4 more
  • Phoenix, Arizona
  • +6 more
2022-03-21
Mar 21, 2022
T
Recruiting
  • CLL
  • +9 more
  • TG-1801
  • Ublituximab
  • Fayetteville, Arkansas
  • +4 more
2022-03-22
Mar 22, 2022
B
Recruiting
  • B-cell Malignancy
  • +4 more
  • Louisville, Kentucky
  • +4 more
2022-03-22
Mar 22, 2022
U
Active, not recruiting
  • Non Hodgkin Lymphoma
  • +8 more
  • Miami, Florida
  • +2 more
2022-03-08
Mar 8, 2022
T
Active, not recruiting
  • Diffuse Large B-Cell Lymphoma
  • +4 more
  • Ublituximab
  • +2 more
  • Birmingham, Alabama
  • +167 more
2022-03-22
Mar 22, 2022
T
Active, not recruiting
  • Follicular Lymphoma
  • Small Lymphocytic Lymphoma
  • Fort Myers, Florida
  • +2 more
2022-03-22
Mar 22, 2022
D
Active, not recruiting
  • Follicular Lymphoma
  • Duarte, California
  • +5 more
2022-03-17
Mar 17, 2022
S
Recruiting
  • Follicular Lymphoma
  • 12 Gy in 6 daily fractions
  • Toronto, Ontario, Canada
    Sunnybrook Health Sciences Centre
2022-03-10
Mar 10, 2022